European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First Revision

European Journal of Neurology - Tập 17 Số 3 - Trang 356-363 - 2010
Peter Van den Bergh1, Robert D.M. Hadden2, P Bouché3, David R. Cornblath4, Andreas Hahn5, Isabel Illa6, Carol Lee Koski7, J.‐M. Léger8, Eduardo Nobile‐Orazio9, J. Pollard10, Claudia Sommer11, Pieter A. van Doorn12, Ivo N. van Schaik13
1Universite Catholique de Louvain
2King's College London
3Consultation de Pathologie Neuromusculaire, Groupe Hospitalier Pitié Salpêtriére, Paris, France
4Johns Hopkins University
5Western University
6Servei Neurologia, Hospital Universitari de la Sta Creu i Sant Pau, Barcelona, Spain
7University of Maryland, Baltimore
8Consultation de Pathologie Neuromusculaire Groupe Hospitalier
9University of Milan
10University of Sydney
11University of Würzburg
12Erasmus University, Rotterdam
13University of Amsterdam#N#

Tóm tắt

Background:  Consensus guidelines on the definition, investigation, and treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have been previously published in European Journal of Neurology and Journal of the Peripheral Nervous System.

Objectives:  To revise these guidelines.

Methods:  Disease experts, including a representative of patients, considered references retrieved from MEDLINE and Cochrane Systematic Reviews published between August 2004 and July 2009 and prepared statements that were agreed in an iterative fashion.

Recommendations:  The Task Force agreed on Good Practice Points to define clinical and electrophysiological diagnostic criteria for CIDP with or without concomitant diseases and investigations to be considered. The principal treatment recommendations were: (i) intravenous immunoglobulin (IVIg) (Recommendation Level A) or corticosteroids (Recommendation Level C) should be considered in sensory and motor CIDP; (ii) IVIg should be considered as the initial treatment in pure motor CIDP (Good Practice Point); (iii) if IVIg and corticosteroids are ineffective, plasma exchange (PE) should be considered (Recommendation Level A); (iv) if the response is inadequate or the maintenance doses of the initial treatment are high, combination treatments or adding an immunosuppressant or immunomodulatory drug should be considered (Good Practice Point); (v) symptomatic treatment and multidisciplinary management should be considered (Good Practice Point).

Từ khóa


Tài liệu tham khảo

10.1002/mus.20022

Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force, 1991, Research criteria for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), Neurology, 41, 617, 10.1212/WNL.41.5.617

10.1111/j.1468-1331.2006.01278.x

10.1002/ana.410110205

10.1111/j.1468-1331.2004.00867.x

10.1016/S1474-4422(08)70299-0

10.1136/jnnp.2009.179358

10.1016/j.jns.2008.11.015

10.1212/01.wnl.0000167549.09664.b8

10.1002/mus.21480

10.1093/brain/110.1.53

10.1136/jnnp.2006.108290

10.1093/brain/awh429

10.1002/mus.20841

10.1016/S0035-3787(05)85195-1

10.1111/j.1529-8027.2009.00226.x

10.1111/j.1085-9489.2005.10306.x

10.1016/j.clinph.2006.05.028

10.1016/j.clinph.2007.06.014

10.1002/mus.21186

10.1212/01.WNL.0000142507.12763.58

10.1002/mus.21078

French CIDP Study Group, 2008, Recommendations on diagnostic strategies for chronic inflammatory demyelinating polyradiculoneuropathy, J Neurol Neurosurg Psychiatry, 79, 115

Mehndiratta MM, 2002, Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy, Cochrane Database Syst Rev, 3, CD002062

10.1002/ana.1088

Eftimov F, 2009, Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy, Cochrane Database Syst Rev, 1, CD001797

10.1007/s004150170093

10.1136/jnnp.62.4.388

10.2165/00003495-200969080-00004

10.1056/NEJM198602203140801

10.1093/brain/119.4.1055

Mehndiratta MM, 2004, Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy (Cochrane Review), Cochrane Database Syst Rev, 3, CD003906

10.1212/WNL.40.2.209

10.1136/jnnp.56.1.36

10.1093/brain/119.4.1067

10.1212/WNL.56.4.445

10.1111/j.1468-1331.2008.02246.x

10.1016/S1474-4422(07)70329-0

10.1002/ana.410360607

10.1212/WNL.35.8.1173

Hughes RAC, 2004, Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy (Update), Cochrane Database Syst Rev, 4, CD003280

10.1212/WNL.53.1.57

10.1212/WNL.60.8_suppl_3.S23

10.1212/WNL.50.1.84

10.1212/WNL.0b013e3181a0fd80

10.1212/WNL.45.8.1628

10.1111/j.1468-1331.2004.00791.x

Thông tin
Thông tin xuất bản

European Journal of Neurology

Tập 17 Số 3

356-363

Thông tin tác giả